BioSpace News Archive

miRagen Therapeutics, Inc. announced that management will be presenting at the Evercore ISI HealthCONx Conference 2019 on Tuesday, December 3rd, taking place at the Four Seasons Hotel in Boston, Massachusetts.

Gritstone Oncology announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present a company overview on Tuesday, December 3, 2019 at 8:30 a.m. ET during the Piper Jaffray 31st Annual Healthcare Conference in New York..

Replimune Group Inc. announced that Philip Astley-Sparke, Executive Chairman and Director of Replimune, will present and host investor meetings at the Piper Jaffray 31st Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY.

Molecular Templates, Inc. announced that Eric Poma, Ph.D., Chief Executive Officer and Chief Scientific Officer, will present a corporate overview at the Evercore ISI HealthCONx Conference, and the Piper Jaffray 31st Annual Healthcare Conference.

CGuard™ EPS clinical data featured as a prominent discussion point in multiple key presentations

Kane Biotech Inc., a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, announced that that it has engaged Kilmer Lucas Inc. to provide the Company with select U.S. and Canadian investor relations and strategic advisory services..

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that the company will present at the Piper Jaffray 31st Annual Healthcare Conference in New York on December 3, 2019 at 2:00 pm ET.

BrainStorm’s Chief Operating and Chief Medical Officer, Ralph Kern MD MHSc, will make a podium presentation at Clinical Trials Session

Presentations will highlight the potential for oral SPR994 to change the treatment landscape in cUTI and the opportunity for oral SPR720 in NTM

Previously, Toujeo was approved only for adults aged 18 years and older.